WebbBackground: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compared with anti-tumor necrosis factor α (TNF-α) therapy. In our study, we evaluated lipids and other … Webb1 juli 2014 · In a systematic review that included data generated from four phase II and four phase III trials, tofacitinib use in approved doses was associated with increases in …

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a ...

WebbWe read the paper by Rimar et al 1 in your journal with great interest. They reported the case with refractory polyarteritis nodosa treated with tofacitinib, a janus kinase inhibitor, … hyperlatria

Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid ...

Webb27 feb. 2024 · Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial Background: Rheumatoid arthritis (RA), a chronic systemic autoimmune disease, is characterized by synovitis and progressive damage to the bone … WebbRheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of … WebbRandomised controlled trials have confirmed the efficacy of tofacitinib (TOFA) and baricitinib (BARI) monotherapies in patients with rheumatoid arthritis (RA) who are … hyperlayer twitch relay